Variation in the Definitions of Urinary Retention in Studies of Intravesical Botulinum Toxin for Idiopathic Overactive Bladder: A Narrative Systematic Review.
Abstract
[PURPOSE] To categorise and quantify definitions of urinary retention reported in studies assessing botulinum toxin (BoNT) injections for idiopathic overactive bladder (iOAB) syndrome.
[MATERIALS AND METHODS] A narrative systematic review was conducted using three databases: EMBASE (via Ovid), PubMed, and SCOPUS. Inclusion criteria comprised studies published as full-text articles in English involving adults receiving BoNT injections (any formulation) for iOAB syndrome, where urinary retention was reported as an outcome.
[RESULTS] From 1986 screened studies, 135 were assessed, and 57 met the eligibility criteria for the narrative systematic review. Reported rates of urinary retention varied widely, ranging from 0% to 42.6%. A definition of urinary retention was provided in 33 studies (57.9%), which were broadly categorised as follows. 1. Post-void residual (PVR) volume threshold: 14 studies (21.5%). 2. Inability to void: 6 studies (9.2%). 3. Initiation of clean intermittent catheterisation (CIC): 6 studies (9.2%). 4. PVR volume threshold and initiation of CIC/indwelling catheterisation (IDC): 6 studies (9.2%). 5. Bladder symptoms and PVR volume threshold and initiation of CIC/IDC: 6 studies (9.2%). 6. Bladder symptoms and PVR volume threshold: 3 studies (4.6%). Notably, 24 studies (42.1%) omitted a definition altogether.
[CONCLUSIONS] Urinary retention rates varied significantly between studies, likely due to the heterogeneous definitions used. The omission of definitions in nearly half of studies further complicates efforts to accurately inform and consent patients regarding the risk of urinary retention and the need for CIC/IDC after intravesical BoNT injection. Standardised definitions are urgently needed to enhance research, improve clinical practice, and support informed patient counselling.
[MATERIALS AND METHODS] A narrative systematic review was conducted using three databases: EMBASE (via Ovid), PubMed, and SCOPUS. Inclusion criteria comprised studies published as full-text articles in English involving adults receiving BoNT injections (any formulation) for iOAB syndrome, where urinary retention was reported as an outcome.
[RESULTS] From 1986 screened studies, 135 were assessed, and 57 met the eligibility criteria for the narrative systematic review. Reported rates of urinary retention varied widely, ranging from 0% to 42.6%. A definition of urinary retention was provided in 33 studies (57.9%), which were broadly categorised as follows. 1. Post-void residual (PVR) volume threshold: 14 studies (21.5%). 2. Inability to void: 6 studies (9.2%). 3. Initiation of clean intermittent catheterisation (CIC): 6 studies (9.2%). 4. PVR volume threshold and initiation of CIC/indwelling catheterisation (IDC): 6 studies (9.2%). 5. Bladder symptoms and PVR volume threshold and initiation of CIC/IDC: 6 studies (9.2%). 6. Bladder symptoms and PVR volume threshold: 3 studies (4.6%). Notably, 24 studies (42.1%) omitted a definition altogether.
[CONCLUSIONS] Urinary retention rates varied significantly between studies, likely due to the heterogeneous definitions used. The omission of definitions in nearly half of studies further complicates efforts to accurately inform and consent patients regarding the risk of urinary retention and the need for CIC/IDC after intravesical BoNT injection. Standardised definitions are urgently needed to enhance research, improve clinical practice, and support informed patient counselling.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | bladder
|
scispacy | 1 | ||
| 해부 | SCOPUS
|
scispacy | 1 | ||
| 해부 | PVR
→ Post-void residual
|
scispacy | 1 | ||
| 약물 | BoNT
→ botulinum toxin
|
C0006055
Botulinum Toxins
|
scispacy | 1 | |
| 약물 | Urinary
|
scispacy | 1 | ||
| 약물 | EMBASE
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] Urinary
|
scispacy | 1 | ||
| 약물 | CIC/IDC
|
scispacy | 1 | ||
| 질환 | Urinary Retention
|
C0080274
Urinary Retention
|
scispacy | 1 | |
| 질환 | Idiopathic Overactive Bladder
|
scispacy | 1 | ||
| 질환 | iOAB syndrome
|
scispacy | 1 | ||
| 질환 | Bladder: A
|
scispacy | 1 | ||
| 기타 | BoNT
→ botulinum toxin
|
scispacy | 1 |
MeSH Terms
Humans; Urinary Retention; Urinary Bladder, Overactive; Administration, Intravesical; Botulinum Toxins, Type A; Neuromuscular Agents; Urinary Bladder; Botulinum Toxins
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.